Story · Medicine & Biotech

Federica Pecci: Predictors of Early Progression on First-Line Osimertinib in EGFR-Mutant NSCLC

1 outlet · first reported by OncoDaily on · latest · 17 hours of coverage

Federica Pecci, Medical Oncologist of Department of Thoracic Oncology at the European Institute of Oncology (IEO), shared on LinkedIn: “Glad to share our manuscript just published in JTO investigating the (OncoDaily)

Coverage, in order

  1. first OncoDaily obscure study peer-reviewed
    Federica Pecci: Predictors of Early Progression on First-Line Osimertinib in EGFR-Mutant NSCLC

    Federica Pecci, Medical Oncologist of Department of Thoracic Oncology at the European Institute of Oncology (IEO), shared on LinkedIn: “Glad to share our manuscript just published in JTO investigating the

  2. OncoDaily obscure study
    Aakash Desai: Predictors of Early Progression With First-Line Osimertinib in EGFR-Mutant NSCLC

    Aakash Desai, Associate Professor at UAB O’Neal Cancer Center, shared on X: “1L osimertinib early PD: EGFRm NSCLC, RWD (n=1488) rwPFS 16.3, mOS 36.7 mo TP53mut aHR 1.68 ex19del vs

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.